AUROPHARMA
Aurobindo Pharma share price & financials
- Price
- ₹1,533.4
- Market cap
- ₹96.7k Cr
- Sector
- Healthcare
- Calls analysed
- 7
Aurobindo Pharma Limited Q1 FY27
What went well
- Consolidated revenues increased by 16% year-on-year to Rs. 9,150 crores, driven by broad-based performance across business areas.
- Operating EBITDA reached Rs. 1,924 crores with a 21% margin, reflecting healthy operating leverage and efficient capital management.
- Gross margin improved to 60.4% from 58.8% in Q1 FY26, benefiting from an improved business mix and operating efficiency.
What to watch
- One-time impact of Rs. 43 crores on Operating EBITDA due to a loss on derecognition of leased residuals.
- Net effective tax rate of 31.9% for the quarter, attributed to not taking tax credit on loss-making subsidiaries, though expected to normalize to 28-29% by year-end.
What Aurobindo Pharma Limited does
Aurobindo Pharma is a Hyderabad-headquartered pharmaceutical company that develops, manufactures and markets generic finished-dosage formulations (oral solids, injectables and specialty products) and active pharmaceutical ingredients (APIs) across therapeutic areas such as CNS, cardiovascular, antibiotics, antiretrovirals, anti-diabetics, gastroenterology, oncology and dermatology. It earns primarily by exporting formulations to the US and Europe, with additional sales to growth markets and ARV tenders, while its API business supplies both its own formulation plants and external customers. The group is also building newer businesses in complex injectables/specialty products (Eugia Pharma), biosimilars (CuraTeQ Biologics) and contract manufacturing of biologics for global pharma partners (TheraNym).
Segments
- Formulations
- Active Pharmaceutical Ingredients (API)
- Biosimilars & Biologics CDMO
- Manufacturing and packaging facilities
- 31 globally
- Countries of presence
- 150+
- R&D centres worldwide
- 9
- Global workforce
- 40,000+
- Formulation (FDF) facilities
- 18
- API & intermediates facilities
- 13
Guidance record · Q1 FY27
what the last two calls moved 20 tracked 4 delivered 3 missed 13 open- M&A Closure Timeline delivered said Q1 FY26 Promised: 9 months as a matter of abundant caution (by Q4 FY26) Q1 FY27: Successfully completed the acquisition during Q1 FY27, ahead of the revised 'early Q2' timeline.
- EBITDA Margin missed said Q3 FY25 Promised: 21% to 22% for FY25 Q1 FY27: Promise relates to FY25 and is concluded. Not discussed.
- Business Inflection Year on track said Q3 FY25 Promised: 2028 to 2030 will be the inflection point Q1 FY27: Progress continues with imminent US filings and 4 approvals in EU/UK/Canada. Management reiterated target of 7-8 products by 2028-29.
All 20 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 16.3%, net profit up 25.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 +6% | 8,646 +8% | 8,853 +6% | 9,150 +16% |
| EBITDA | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 +7% | 1,773 +12% | 1,750 −1% | 1,880 +17% |
| Net profit | 817 | 846 | 903 | 824 | 848 +4% | 910 +8% | 921 +2% | 1,032 +25% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +59.9% 1Y
1Y: ₹1,050.3 on 10 Sept 2025 → ₹1,679.8. High ₹1,717 (31 Aug 2026), low ₹1,050.3 (10 Sept 2025).
How the price took the results
close before → close after
- Q1 FY27
- −1.5%
- 6 Aug
- Q4 FY26
- −5.4%
- 22 May
- Q3 FY26
- −6.6%
- 10 Feb
- Q2 FY26
- −0.7%
- 6 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 10.6% a year over 3 years, FY23 to FY26. Operating margin widened to 20.2%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹24.9k Cr | ₹29.0k Cr | ₹31.7k Cr | ₹33.7k Cr |
| Operating profit | ₹3.7k Cr | ₹5.8k Cr | ₹6.5k Cr | ₹6.8k Cr |
| Operating margin | 14.8% | 19.9% | 20.6% | 20.2% |
| Interest | ₹141 Cr | ₹290 Cr | ₹457 Cr | ₹384 Cr |
| Depreciation | ₹1.2k Cr | ₹1.5k Cr | ₹1.6k Cr | ₹1.8k Cr |
| Net profit | ₹1.9k Cr | ₹3.2k Cr | ₹3.5k Cr | ₹3.5k Cr |
| Net margin | 7.8% | 10.9% | 11.0% | 10.4% |
| Cash from operations | ₹2.4k Cr | ₹2.4k Cr | ₹3.9k Cr | ₹5.5k Cr |
| Free cash flow | ₹-323 Cr | ₹-1.1k Cr | ₹1.4k Cr | ₹2.5k Cr |
| ROCE | 9.0% | 14.0% | 14.0% | 13.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹58 Cr | ₹58 Cr |
| Reserves | ₹21.9k Cr | ₹24.5k Cr | ₹26.8k Cr | ₹29.8k Cr | ₹35.0k Cr | ₹37.8k Cr |
| Borrowings | ₹5.3k Cr | ₹2.9k Cr | ₹5.3k Cr | ₹6.6k Cr | ₹7.8k Cr | ₹8.1k Cr |
| Other liabilities | ₹6.1k Cr | ₹6.2k Cr | ₹7.4k Cr | ₹8.2k Cr | ₹9.7k Cr | ₹12.2k Cr |
| Total liabilities | ₹33.4k Cr | ₹33.6k Cr | ₹39.5k Cr | ₹44.7k Cr | ₹52.5k Cr | ₹58.2k Cr |
| Fixed assets | ₹9.4k Cr | ₹10.5k Cr | ₹11.0k Cr | ₹14.5k Cr | ₹17.7k Cr | ₹17.4k Cr |
| Capital work in progress | ₹3.1k Cr | ₹3.7k Cr | ₹5.4k Cr | ₹3.9k Cr | ₹3.0k Cr | ₹5.2k Cr |
| Investments | ₹591 Cr | ₹997 Cr | ₹543 Cr | ₹372 Cr | ₹268 Cr | ₹1.1k Cr |
| Other assets | ₹20.4k Cr | ₹18.4k Cr | ₹22.5k Cr | ₹26.0k Cr | ₹31.5k Cr | ₹34.5k Cr |
| Total assets | ₹33.4k Cr | ₹33.6k Cr | ₹39.5k Cr | ₹44.7k Cr | ₹52.5k Cr | ₹58.2k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, FIIs added +2.00 pp while DIIs trimmed −1.88 pp. The shareholder count shrank 12% to 2,39,073.
- Promoters
- 51.9%
- FIIs
- 16.4%
- DIIs
- 25.1%
- Government
- 0.1%
- Public
- 6.6%
Since Jun 2025
- FIIs +2.00 pp
- DIIs −1.88 pp
- Public −0.25 pp
How it drifted, 12 quarters
Over this window DIIs went from 18.3% to 25.1% — +6.8 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 51.8%, FIIs 22.4%, DIIs 18.3%, Public 7.4%.Dec '23: Promoters 51.8%, FIIs 20.7%, DIIs 20.6%, Public 6.8%.Mar '24: Promoters 51.8%, FIIs 18.0%, DIIs 23.3%, Public 6.9%.Jun '24: Promoters 51.8%, FIIs 16.7%, DIIs 24.8%, Public 6.7%.Sep '24: Promoters 51.8%, FIIs 16.6%, DIIs 25.1%, Public 6.5%.Dec '24: Promoters 51.8%, FIIs 16.3%, DIIs 25.2%, Public 6.7%.Mar '25: Promoters 51.8%, FIIs 15.3%, DIIs 26.2%, Public 6.6%.Jun '25: Promoters 51.8%, FIIs 14.4%, DIIs 26.9%, Public 6.9%.Sep '25: Promoters 51.8%, FIIs 14.2%, DIIs 27.6%, Public 6.4%.Dec '25: Promoters 51.8%, FIIs 13.9%, DIIs 27.7%, Government 0.0%, Public 6.5%.Mar '26: Promoters 51.8%, FIIs 15.2%, DIIs 25.8%, Government 0.1%, Public 7.1%.Jun '26: Promoters 51.9%, FIIs 16.4%, DIIs 25.1%, Government 0.1%, Public 6.6%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Quant Mutual Fund Mutual fund newly disclosed 4.96% held
- SBI Large & Midcap Fund Mutual fund newly disclosed 3.57% held
- HDFC Mutual Fund Mutual fund newly disclosed 3.22% held
- NPS Trust - A/C SBI Pension Fund Scheme - NPS Tier Pension / PF newly disclosed 2.74% held
- Kambam Surya Prakash Reddy newly disclosed 0.00% held
The same filing shows 0 holders trimming and 5 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Aurobindo Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding) | 33.54% | unchanged |
| Quant Mutual Fund Mutual fund | 4.96% | newly disclosed |
| Kambam Nithyananda Reddy | 4.37% | unchanged |
| SBI Large & Midcap Fund Mutual fund | 3.57% | newly disclosed |
| Kirthi Reddy Kambam | 3.46% | unchanged |
| HDFC Mutual Fund Mutual fund | 3.22% | newly disclosed |
| Venkata Ramprasad Reddy Penaka | 3.07% | unchanged |
| Life Insurance Corporation Of India Insurer | 2.94% | unchanged |
| Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd. (Jointly Holding) | 2.86% | unchanged |
| NPS Trust - A/C SBI Pension Fund Scheme - NPS Tier Pension / PF | 2.74% | newly disclosed |
| M Sivakumaran | 2.48% | unchanged |
| Kambam Spoorthi | 1.20% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in AUROPHARMA
Filings to Aug 2026
0 new, 11 added, 7 trimmed, 0 sold out — net −6.93 L shares (−2.3%).
- Held by funds
- ₹4.9k Cr
- 28 schemes
- Biggest holder
- SBI Large and Midcap Fund
- ₹807 Cr · 1.9% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| SBI Large and Midcap Fund SBI Mutual Fund | ₹807 Cr | −6.57 L | Jul '25 |
| SBI Flexicap Fund SBI Mutual Fund | ₹688 Cr | held | Apr '26 |
| SBI Midcap Fund SBI Mutual Fund | ₹522 Cr | held | Apr '26 |
| HDFC Balanced Advantage Fund HDFC Mutual Fund | ₹427 Cr | held | Dec '22 |
| HDFC Large and Mid Cap Fund HDFC Mutual Fund | ₹341 Cr | held | Dec '22 |
| SBI Contra Fund SBI Mutual Fund | ₹269 Cr | held | Aug '21 |
| SBI ELSS Tax Saver Fund SBI Mutual Fund | ₹258 Cr | held | May '26 |
| SBI Healthcare Opportunities Fund SBI Mutual Fund | ₹226 Cr | −0.02 L | Mar '26 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
11 added, 7 trimmed — net −6.93 L shares (−2.3%)
- Funds are sitting on
- +28%
- vs est. average cost
- Held by funds
- ₹4.9k Cr
- 28 schemes · ≈ 4.6% of the company
- Biggest holder
- SBI Large and Midcap Fund
- ₹807 Cr · 1.9% of that fund
- Longest holder
- Nippon India Arbitrage Fund
- 11y 7m · since Feb '15
Shares held by these funds +29%
Aug '23 2.96 cr shares Jul '26
What the price assumes
AttractiveTo justify its price of ₹1680, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~22%. At that growth it is worth ₹2026 — upside of 21%.
- Growth the price implies
- 18.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 22.0% a year
- net profit, FY23–FY26 · EPS 22.4%
- The gap
- -0.0 pp
- 21% downside if it only repeats history
All earnings calls (7)
Read the Q1 FY27 call →Learn to analyse Aurobindo Pharma Limited
Guides on how to read this kind of business and the numbers that matter.